REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV itolizumab Trial: RESURRECT

<p>Datasets pertaining to the manuscript,&nbsp;Original Research, entitled &ldquo;<strong>RE</strong>covery and <strong>SUR</strong>vival of patients with moderate to severe acute <strong>RE</strong>spiratory distress syndrome (ARDS) due to <strong>C</strong>OVID-19: a multicentre, single-arm, Phase IV Itolizumab <strong>T</strong>rial: <strong>RESURRECT</strong>&rdquo; are submitted here.&nbsp;&nbsp;</p>